Insights Newsletter May 2026: Emerging Trends for Clinical Leadership

This month’s Insights Newsletter covers the latest practice-changing pharmacy updates, emerging trends, and popular natural medicine topics and resources. 

New Oral GLP-1 Agonist, Orforglipron

Teams will need to be ready with guidance about orforglipron, the second oral GLP-1 receptor agonist approved for adults who are overweight or obese. Our articles discuss orforglipron’s dosing, administration, efficacy, and side effects, and how it compares to the other oral GLP-1 agonist, semaglutide. We also give guidance about patient counseling and error prevention. Readers can see how orforglipron stacks up with our GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart and Comparison of Weight Loss Products resource. Read More

Community Pharmacies: New Cholesterol Guidelines – Screening, Risk, and Targets

Big changes in guidelines will bring up questions about managing cholesterol for primary CV prevention. Our articles give guidance about when to screen patients with a lipid panel and how to estimate CV risk in patients without CV disease. We also discuss treatment considerations and LDL targets. Readers can get more guidance in our updated Cholesterol Guidelines resource. Read More

Hospitals: Updated Sepsis Guidelines  

Hospitals will need to revise their adult sepsis protocols due to updated guidelines. Our articles review key practice changes such as tighter antibiotic-timing targets. We also outline blood pressure goals, when to consider GI decontamination, and considerations about antibiotic de-escalation. Readers can dive deeper into sepsis treatment in our updated resource, Sepsis Management in Adults. Read More

NatMed: Sea Moss 101: Separating the Hype from the Hard Evidence

Patients are asking about sea moss after seeing celebrities and influencers promote it for everything from skin health to gut health and immune support. Our NatMed article breaks down what sea moss is and what the evidence actually shows. The bottom line: there are no well-designed clinical trials supporting sea moss for any specific condition. It’s likely safe in food amounts for most people, but patients with thyroid conditions or those taking thyroid medications like levothyroxine should be cautious due to its variable iodine content. Supplements are a bigger concern since many don’t specify iodine content. Read More

Pharmacy & Prescriber Podcasts

Medication Talk

Listen to this month’s podcast episode, GLP-1 Agonists: Clinical Conundrums, as our expert panel tackles real-world questions about GLP-1 agonists, from starting them and setting expectations with patients to strategies for switching agents. You’ll also hear them review key considerations to limit muscle loss with GLP-1 agonist use and discuss why some patients hit a plateau or don’t respond to GLP-1 agonists. Read More

Rumor vs Truth

Listen to the latest episode, Artificial Intelligence, as our editors put artificial intelligence under the microscope—cutting through hype to examine how AI is actually performing in healthcare today. Read More

Clinical Capsules

Listen to our latest episode, Managing Opioid Overdose: Signs, Symptoms, and Reversal Agents, as TRC Healthcare Associate Editor and Clinical Pharmacist Don Weinberger, PharmD, PMSP, discusses how to recognize opioid overdose, compares naloxone and nalmefene options including the new nalmefene auto-injector, and shares tips for patients and caregivers on using opioid reversal agents effectively. Read More

Be sure to listen to our new Natural Medicines: Evidence in Practice podcast on Migraines: Counseling Patients on Natural Treatment Options, discover the latest specialty pharmacy courses that launched this week, don’t miss out on our upcoming live CE webinars, and more. Read More